Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
– Company to Hold Event During ASH –
– CG-806 Preclinical Abstracts Accepted for Presentation –
SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company will be hosting an Event at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2019 in Orlando, FL. More details will be provided closer to ASH. In addition, preclinical data for its pan-FLT3/pan-BTK inhibitor CG-806 will be presented in two separate posters.
The abstracts accepted for presentation are listed below and can be viewed online at the ASH conference website.
CG-806 Poster Presentation Details
Presentation Title: CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells (link)
Date & Time: Sunday December 8, 2019, 6:00-8:00 PM ETSession Name: 642. CLL: Therapy, Excluding Transplantation: Poster IIPublication #: 3051Location: Orange County Convention Center, Hall B
Presentation Title: Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas (link)
Date & Time: Monday, December 9, 2019, 6:00-8:00 PM ETSession Name: 605 Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster IIIPublication #: 3802Location: Orange County Convention Center, Hall B
The two poster abstracts also will be published in the November supplemental issue of Blood, an ASH journal, available online.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the clinical potential and favorable properties of CG-806, and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact:
Aptose BiosciencesGreg ChowExecutive Vice President, CFO650firstname.lastname@example.org
SMP CommunicationsSusan Pietropaolo201email@example.com
LifeSci Advisors, LLCDaniel FerryManaging Director617-535-7746Daniel@lifesciadvisors.com